TAYSHA GENE THERAPIES INC (TSHA)
Sector: Health Care
2026 Annual Meeting Analysis
TAYSHA GENE THERAPIES INC · Meeting: June 1, 2026
Directors FOR
2
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Class III Directors
Nolan has served as CEO and director since 2022 and 2020 respectively; TSHA's 3-year stock return of +770.4% outpaces the XBI — SPDR S&P Biotech ETF return of +68.6% by approximately +702 percentage points, far exceeding the 65-point threshold required to trigger an against vote under the strong-positive TSR tier, so no TSR concern applies; no overboarding, attendance, or independence issues were identified.
Sepp-Lorenzino has served as an independent director since November 2020 and brings deep scientific expertise in nucleic acid and genomic medicine therapies directly relevant to Taysha's gene therapy focus; TSHA's 3-year return of +770.4% far exceeds the XBI — SPDR S&P Biotech ETF's +68.6% return, so the TSR trigger does not apply; she is independent, serves on appropriate committees, and no attendance or overboarding issues were identified.
Both Class III nominees are well-qualified for a gene therapy company, no TSR underperformance concern applies given TSHA's extraordinary 3-year return of +770.4% versus the XBI — SPDR S&P Biotech ETF benchmark of +68.6%, and no overboarding, attendance, or independence red flags were found for either nominee.
Say on Pay
✓ FORCEO
Sean Nolan
Total Comp
$4,099,065
Prior Support
N/A
CEO Sean Nolan received total compensation of $4,099,065 for 2025, which is reasonable for a biotech CEO at a $1.9 billion market cap company; the pay mix is appropriate, with base salary of $645,840 (approximately 16% of total) well below the 40% fixed-pay threshold, and the majority of pay delivered through performance-linked equity awards and bonuses. The company's stock rose over 770% over three years versus the XBI — SPDR S&P Biotech ETF's 69% gain, demonstrating strong pay-for-performance alignment; the notable concern is that the CEO's children and sister-in-law are employed by the company in roles that could create conflicts, but this is a governance matter rather than a direct compensation structure failure, and the compensation program structure itself passes policy screens.
Auditor Ratification
✓ FORAuditor
Deloitte & Touche LLP
Tenure
6 yrs
Audit Fees
$943,442
Non-Audit Fees
$2,051
Non-audit fees of $2,051 represent less than 1% of audit fees of $943,442, well below the 50% threshold that would raise independence concerns; Deloitte has audited Taysha since 2020 (approximately 6 years), far below the 25-year tenure trigger; Deloitte is a Big 4 firm appropriate for a $1.9 billion market cap company; no material restatements were identified.
Overall Assessment
Taysha Gene Therapies' 2026 annual meeting presents a straightforward ballot: both director nominees are well-qualified with strong relevant experience and the company's extraordinary stock performance relative to the XBI — SPDR S&P Biotech ETF eliminates any TSR concern; the auditor fees are clean, the compensation program is reasonably structured with strong pay-for-performance alignment, and the only notable governance flag is the CEO's employment of family members in non-trivial roles, which warrants monitoring but does not change any vote determination under this policy.